A Phase 2 interventional study of Lemborexant 10 MG and Placebo in Insomnia, sponsored by Woolcock Institute of Medical Research. Recruiting at 1 site in Australia. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Woolcock Institute of Medical Research · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing lemborexant in Sleep Initiation and Maintenance Disorders — 8 open to participants now, 8 under way, none of them phase 3. lemborexant · Sleep Initiation and Maintenance Disorders.
Among the 21 studies testing lemborexant in Sleep Initiation and Maintenance Disorders, this one is the 20th largest by planned enrollment, is one of 4 that started in 2025, is one of 8 in phase 2, and was the 16th registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →8 of the 21 studies testing lemborexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18+
Laval University · Sites in Canada
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Beijing Tiantan Hospital
Ages 50–80
Beijing Tiantan Hospital
Ages 18–65
By country, each count listing its studies:
lemborexant: first FDA approval 2019 (DAYVIGO). What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 40 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 20 is below the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 82 across the 21 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 21 have an industry lead sponsor. The 10 most frequent:
Woolcock Institute of Medical Research is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
10 studies in Sleep Initiation and Maintenance Disorders by Woolcock Institute of Medical Research: 7 open now, 7 under way, none of them phase 3. Of 3 finished, 0 (0%) have results posted.
Among the 10 studies in Sleep Initiation and Maintenance Disorders by Woolcock Institute of Medical Research, this one is the 6th largest by planned enrollment, is one of 4 that started in 2025, is one of 2 in phase 2, and was the 8th registered.
Woolcock Institute of Medical Research’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2022.
3 of the studies testing lemborexant in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
| NCT06779149Laval UniversityEfficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia | 2027-02 |
| NCT06648681University of British ColumbiaLemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing lemborexant in Sleep Initiation and Maintenance Disorders, from their registry updates:
Among Woolcock Institute of Medical Research’s 10 in Sleep Initiation and Maintenance Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to explore the potential neuroprotective benefits of a dual orexin receptor antagonist (DORA) in adults with insomnia. The main questions it aims to answer are:
Participants will:
This is a randomised placebo-controlled cross-over study of a dual orexin receptor antagonist (DORA) versus placebo in adults with insomnia.
To be enrolled in the study, participants are required to complete an online pre-screening survey. Eligible participants will be directed to a separate webpage where they will be invited to review and download the Participant Information Sheet (PIS) and asked to provide their contact details and consent for a follow up call/email from the research team to book in a screening visit. At the screening visit the study team will explain the study to each participant and ensure they have had ample time prior to the visit to read and understand the PIS and have had the opportunity to ask any questions. The consent form will be signed by both the participant and a medical officer and participants will be randomised into their first treatment period; DORA (Lemborexant) or placebo.
Participants will take the treatment orally, nightly for 2 weeks. There will be a 2-4 week washout period between treatments. At the conclusion of both two-week treatment phases, participants will attend the laboratory for an overnight visit. The visit will take approximately 18 hours (including sleep time). During this visit, participants will partake in a number of assessments including HD-EEG, fNIRS, questionnaires and pupillometry. Participants will also have blood samples collected in the morning of the overnight study (hourly for four hours).
The study will recruit primarily through social media advertisements. The study will be coordinated from the Woolcock Institute of Medical Research, Sydney, Macquarie University, NSW, 2113, Australia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10mg Lemborexant tablet taken orally, nightly for two weeks
Drug: Lemborexant 10 MG
Matching placebo tablet taken orally, nightly for two weeks
Drug: Placebo
An orally ingested tablet containing 10mg Lemborexant taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
Also known as: Dayvigo
Placebo tablets will contain similar excipients without the active ingredient (Lemborexant) and manufactured under the same condition as the active. Placebo tablets, packs and instructions will be identical in every respect to enable the double-blind study design.
Blood levels of TAU181
Morning blood-based phosphorylated TAU (standardised pTAU181:TAU181 ratio)
Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.
Blood levels of TAU217
Morning blood-based phosphorylated TAU217, analysed within each participant.
Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.
Blood levels of Beta amyloid
Morning blood-based Beta Amyloid 40:42 ratio, analysed within each participant.
Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.
Blood levels of NFL
Morning blood-based Neurofilament Light Chain (NFL), analysed within each participant.
Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.
Blood levels of GFAP
Morning blood-based Fibrillary Acidic Protein (GFAP), analysed within each participant.
Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.
Absolute Electroencephalographic (EEG) Power During Non-Rapid Eye Movement (NREM) (stages 2 and 3) and REM sleep.
High-density EEG, spectral power for frequency ranges low-delta: 0.5-1 Hz; delta: 1-4.5 Hz; theta: 4.5-8Hz; alpha: 8-12Hz; sigma: 12-15 Hz; beta: 15-25 Hz; gamma: 25-40 Hz. Absolute Electroencephalographic (EEG) Power During Non-Rapid Eye Movement (NREM) and REM sleep (12 statistical comparisons). Unit of measurement is μV\^2.
Time frame: 14th night after treatment starts.
Plan to share: Yes — Non-identifiable IPD will be shared upon reasonable request to the Principal Investigators.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Non-identifiable IPD will become available one year after the Actual Study Completion Date and will be available for ten years.
Access criteria: A copy of the non-identifiable dataset may be requested by academic collaborators not affiliated with the WIMR through a data request form which outlines the investigators, aims and hypotheses, data to be included, a statistical analysis plan, ethics approval, and security measures. Contact the Coordinating Principal Investigator for access to data.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.
Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 31 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lemborexant
Sleep Initiation and Maintenance Disorders →
Woolcock Institute of Medical Research